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Background
Safety and efficacy of once-daily 20 mg tafamidis, a
transthyretin (TTR) stabilizer, was evaluated in an
18-month, multicentre, randomized, double-blind, pla-
cebo-controlled study in 128 patients with early sympto-
matic V30M TTR familial amyloid polyneuropathy
(TTR-FAP). In the intent-to-treat population, a respon-
der analysis for Neuropathy Impairment Score-Lower
Limb (NIS-LL) (co-primary with Norfolk Quality of
Life-Diabetic Neuropathy) favoured tafamidis (P=0.07).
A pre-specified, key secondary analysis of change from
baseline to Month 18 in NIS-LL continuous scores was
significant (P=0.04). Placebo-corrected point estimates
for 5 pre-specified and validated measures of disease
progression also favoured tafamidis and were direction-
ally consistent. Additional post-hoc analyses supporting
tafamidis for delaying progression of TTR-FAP are
reported here.
Methods
Change from baseline in NIS-LL over time was analysed
with the addition of the baseline values as a covariate in
a repeated measures model. A sensitivity multiple impu-
tation analysis with imputed values based on assigned
treatment group was also performed. Additionally,
change in NIS-LL+ summated 7 (neurophysiological
function composite endpoint) over time was assessed.
Results
When adjusted for baseline NIS-LL disease severity, sta-
tistical significance in change from baseline to Month
18 NIS-LL was retained. The magnitude of separation
between placebo and tafamidis was consistent across the
full range of baseline values (least squares mean differ-
ence = 2.7 points; 95% confidence interval [CI]: 0.1, 5.2;
P<0.05). Treatment effect estimates from the multiple
imputation analysis, although reduced, were similar to
those from the analysis of change from baseline to
Month 18, and remained significant. With each batch
run representing the results combined from 1000 multi-
ply imputed data sets, the difference in NIS-LL change
from baseline to Month 18 for tafamidis versus placebo
was -2.787 (standard error [SE]: 1.345; 95% CI: -5.423,
-0.151; P=0.04) for Batch Run 1; for Batch Run 2, the
difference was -2.815 (SE: 1.351; 95% CI: -5.464, -0.166;
P=0.04); and for Batch Run 3, the difference was -2.798
(SE: 1.347; 95% CI: -5.438, -0.157; P=0.04). For NIS-LL+
summated 7, at Month 6, the mean change (standard
deviation) was 1.8 (4.82) for the tafamidis group and
4.0 (7.12) for the placebo group (P=0.053); while signifi-
cant differences between treatment groups were
observed at Months 12 (1.6 [5.27] vs 7.8 [8.87],
P=0.00009) and 18 (3.4 [5.95] vs 8.8 [10.44], P=0.0043).
Conclusions
The beneficial effects of tafamidis in delaying neurologi-
cal impairment in TTR-FAP are further supported by
these post-hoc analyses.
Note
Note: First presented at the 1st Congress of the European
Academy of Neurology, Berlin, Germany, June 2015
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